Alvotech Share Price

Equities

ALVO

LU2458332611

Biotechnology & Medical Research

End-of-day quote Nasdaq 23:00:00 30/04/2024 BST 5-day change 1st Jan Change
14.48 USD -0.14% Intraday chart for Alvotech +6.08% +26.13%
Sales 2024 * 356M 28.35B Sales 2025 * 606M 48.32B Capitalization 4.06B 323B
Net income 2024 * -149M -11.87B Net income 2025 * 30M 2.39B EV / Sales 2024 * 15.5 x
Net Debt 2024 * 1.46B 116B Net Debt 2025 * 1.28B 102B EV / Sales 2025 * 8.79 x
P/E ratio 2024 *
-24.3 x
P/E ratio 2025 *
140 x
Employees 999
Yield 2024 *
-
Yield 2025 *
-
Free-Float 27.24%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Alvotech

1 day-0.14%
1 week+6.08%
Current month-0.14%
1 month+27.02%
3 months-7.77%
6 months+62.70%
Current year+26.13%
More quotes
1 week
14.20
Extreme 14.2
14.76
1 month
11.19
Extreme 11.19
14.76
Current year
11.01
Extreme 11.0101
18.00
1 year
6.70
Extreme 6.7
18.00
3 years
5.20
Extreme 5.2
18.00
5 years
5.20
Extreme 5.2
18.00
10 years
5.20
Extreme 5.2
18.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 01/11/18
Director of Finance/CFO 46 31/01/20
Chief Tech/Sci/R&D Officer - 31/12/22
Members of the board TitleAgeSince
Director/Board Member 68 15/06/22
General Counsel 57 30/04/20
Chief Executive Officer 54 01/11/18
More insiders
Date Price Change Volume
02/05/24 14.51 +0.21% 231,629
01/05/24 14.48 -0.14% 118,095
30/04/24 14.5 +1.97% 224,692
29/04/24 14.22 +0.49% 39,632
26/04/24 14.15 +3.66% 248,476

End-of-day quote Nasdaq, May 30, 2024

More quotes
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
14.51 USD
Average target price
16.5 USD
Spread / Average Target
+13.71%
Consensus

Annual profits - Rate of surprise